vs
安捷伦科技（A）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是登士柏西诺德的1.9倍（$1.8B vs $961.0M）。安捷伦科技净利率更高（17.0% vs -15.2%，领先32.2%）。安捷伦科技同比增速更快（7.0% vs 6.2%）。安捷伦科技自由现金流更多（$175.0M vs $60.0M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs 0.4%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
A vs XRAY — 直观对比
营收规模更大
A
是对方的1.9倍
$961.0M
营收增速更快
A
高出0.8%
6.2%
净利率更高
A
高出32.2%
-15.2%
自由现金流更多
A
多$115.0M
$60.0M
两年增速更快
A
近两年复合增速
0.4%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $961.0M |
| 净利润 | $305.0M | $-146.0M |
| 毛利率 | 52.6% | 46.1% |
| 营业利润率 | 19.6% | -14.5% |
| 净利率 | 17.0% | -15.2% |
| 营收同比 | 7.0% | 6.2% |
| 净利润同比 | -4.1% | 66.0% |
| 每股收益（稀释后） | $1.07 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRAY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $961.0M | ||
| Q3 25 | $1.7B | $904.0M | ||
| Q2 25 | $1.7B | $936.0M | ||
| Q1 25 | $1.7B | $879.0M | ||
| Q4 24 | $1.7B | $905.0M | ||
| Q3 24 | $1.6B | $951.0M | ||
| Q2 24 | $1.6B | $984.0M |
净利润AXRAY
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-146.0M | ||
| Q3 25 | $336.0M | $-427.0M | ||
| Q2 25 | $215.0M | $-45.0M | ||
| Q1 25 | $318.0M | $20.0M | ||
| Q4 24 | $351.0M | $-430.0M | ||
| Q3 24 | $282.0M | $-494.0M | ||
| Q2 24 | $308.0M | $-4.0M |
毛利率AXRAY
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 46.1% | ||
| Q3 25 | 51.1% | 48.8% | ||
| Q2 25 | 51.9% | 52.4% | ||
| Q1 25 | 53.5% | 53.0% | ||
| Q4 24 | 53.9% | 49.3% | ||
| Q3 24 | 54.2% | 52.1% | ||
| Q2 24 | 54.4% | 51.9% |
营业利润率AXRAY
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -14.5% | ||
| Q3 25 | 20.7% | -24.1% | ||
| Q2 25 | 18.0% | -13.7% | ||
| Q1 25 | 22.4% | 7.2% | ||
| Q4 24 | 24.0% | -56.2% | ||
| Q3 24 | 21.1% | -48.6% | ||
| Q2 24 | 23.1% | 5.1% |
净利率AXRAY
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -15.2% | ||
| Q3 25 | 19.3% | -47.2% | ||
| Q2 25 | 12.9% | -4.8% | ||
| Q1 25 | 18.9% | 2.3% | ||
| Q4 24 | 20.6% | -47.5% | ||
| Q3 24 | 17.9% | -51.9% | ||
| Q2 24 | 19.6% | -0.4% |
每股收益（稀释后）AXRAY
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.74 | ||
| Q3 25 | $1.18 | $-2.14 | ||
| Q2 25 | $0.75 | $-0.22 | ||
| Q1 25 | $1.11 | $0.10 | ||
| Q4 24 | $1.23 | $-2.09 | ||
| Q3 24 | $0.97 | $-2.46 | ||
| Q2 24 | $1.05 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $326.0M |
| 总债务越低越好 | $3.0B | $2.3B |
| 股东权益账面价值 | $6.9B | $1.3B |
| 总资产 | $12.8B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.44× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资AXRAY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $326.0M | ||
| Q3 25 | $1.5B | $363.0M | ||
| Q2 25 | $1.5B | $359.0M | ||
| Q1 25 | $1.5B | $398.0M | ||
| Q4 24 | $1.3B | $272.0M | ||
| Q3 24 | $1.8B | $296.0M | ||
| Q2 24 | $1.7B | $279.0M |
总债务AXRAY
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $2.3B | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AXRAY
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $1.3B | ||
| Q3 25 | $6.4B | $1.5B | ||
| Q2 25 | $6.1B | $2.0B | ||
| Q1 25 | $6.0B | $2.0B | ||
| Q4 24 | $5.9B | $1.9B | ||
| Q3 24 | $5.9B | $2.5B | ||
| Q2 24 | $6.2B | $3.1B |
总资产AXRAY
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $5.4B | ||
| Q3 25 | $12.2B | $5.7B | ||
| Q2 25 | $12.2B | $6.1B | ||
| Q1 25 | $11.9B | $6.0B | ||
| Q4 24 | $11.8B | $5.8B | ||
| Q3 24 | $11.0B | $6.6B | ||
| Q2 24 | $10.9B | $6.9B |
负债/权益比AXRAY
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.70× | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | 0.90× | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $60.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 6.2% |
| 资本支出强度资本支出/营收 | 5.2% | 4.3% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | $104.0M |
8季度趋势，按日历期对齐
经营现金流AXRAY
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $101.0M | ||
| Q3 25 | $362.0M | $79.0M | ||
| Q2 25 | $221.0M | $48.0M | ||
| Q1 25 | $431.0M | $7.0M | ||
| Q4 24 | $481.0M | $87.0M | ||
| Q3 24 | $452.0M | $141.0M | ||
| Q2 24 | $333.0M | $208.0M |
自由现金流AXRAY
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $60.0M | ||
| Q3 25 | $259.0M | $40.0M | ||
| Q2 25 | $107.0M | $16.0M | ||
| Q1 25 | $334.0M | $-12.0M | ||
| Q4 24 | $388.0M | $36.0M | ||
| Q3 24 | $360.0M | $98.0M | ||
| Q2 24 | $230.0M | $156.0M |
自由现金流率AXRAY
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 6.2% | ||
| Q3 25 | 14.9% | 4.4% | ||
| Q2 25 | 6.4% | 1.7% | ||
| Q1 25 | 19.9% | -1.4% | ||
| Q4 24 | 22.8% | 4.0% | ||
| Q3 24 | 22.8% | 10.3% | ||
| Q2 24 | 14.6% | 15.9% |
资本支出强度AXRAY
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 4.3% | ||
| Q3 25 | 5.9% | 4.3% | ||
| Q2 25 | 6.8% | 3.4% | ||
| Q1 25 | 5.8% | 2.2% | ||
| Q4 24 | 5.5% | 5.6% | ||
| Q3 24 | 5.8% | 4.5% | ||
| Q2 24 | 6.5% | 5.3% |
现金转化率AXRAY
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | 0.35× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
